Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
Hybrid AI Approach Cuts Mammography Workload by 38%
A Dutch research team demonstrated that a 'hybrid' AI strategy can reduce radiologist workload in mammography screening by nearly 40% without affecting performance.
•AuntMinnie
Hybrid AI-Human Mammography Reading Cuts Workload Without Compromising Cancer Detection
A hybrid AI and radiologist reading strategy for screening mammography reduced radiologist workload by 38% without affecting recall or cancer detection rates.
•Health Imaging
AI as Second Reader Surpasses Radiologists in Breast Cancer Screening
AI used as a second reader on mammograms improves cancer detection rates compared to radiologists alone.